Latest Methylphenidate Stories
PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch DaytranaÂ®.
Fruit flies may seem like unlikely heroes in the battle against drug abuse, but new research suggests that these insects â€” already used to study dozens of human disease â€” could claim that role.
Finding may provide new insights into the neurological basis of ADHD, learning deficits, and more.
Primary objective of the study was to evaluate the safety of coadministration of INTUNIV with stimulants.
PHILADELPHIA, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology.
LAS VEGAS, Nov.
Following is a summary of the key Shire scientific presentations.
TITUSVILLE, N.J., Sept. 9 /PRNewswire/ -- Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children(1) and 4 percent of adults in the U.S.(2) Recent studies suggest ADHD is underdiagnosed: researchers estimate up to 20 percent of U.S.